Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:37:36.943Z.
Consensus retrieved: 2026-10-06T12:52:42.483Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:37:36.943Z.
Quote observation: 2026-10-06T16:35:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f23401f377ae0c42cb4058dfce1620411e9c781823cb8ffdb9eedba1333334c1
Forward PE Ratio (N/A) = Dated Quote Price ($13.26) / Consensus Forward EPS ($-0.45)
FORWARD PE RATIO
N/A
Iovance Biotherapeutics, Inc.
Market Cap
$5.92B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | $5.92B | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 31.70 |
| GRAIL Inc. (GRAL)vs › | $6.05B | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 54.07 |
| CG Oncology Inc. (CGON)vs › | $5.69B | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | 136.85 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.53B | 29.23 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.31B | N/A |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 18.46 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.51B | 19.92 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $13.26, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.45 | $-0.55 – $-0.30 | 6 | n/m |
| 2027-12-31 | $-0.21 | $-0.37 – $-0.09 | 6 | n/m |
| 2028-12-31 | $0.17 | $-0.18 – $0.51 | 5 | 77.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
